American Oriental (AOB) Reports Q3 EPS In-Line
More News related to AOB
- Roth Capital Starts American Oriental Bioengineering (AOB) at Buy
- American Oriental (AOB) Reports Q3 EPS In-Line
- American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
- Lazard Downgrades American Oriental (AOB) to Hold
- Matrix USA Rating Changes 9/2
More News related to Earnings
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
American Oriental (NYSE: AOB) reports Q3 EPS of $0.21, cents better than the analyst estimate of $0.21. Revenue for the quarter was $70.6 million, versus the consensus of $67.63 million.
American Oriental Bioengineering, Inc. is an integrated, pharmaceutical company engaged in the development, manufacture and commercialization of a range of pharmaceutical and healthcare products.
Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!
Related Categories
EarningsStocks Mentioned
-0.26Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
